Medical Oncology
State-of-the-Art Systemic Cancer Therapy - Personalized for Every Patient.
Targeted therapies, immunotherapy, and precision chemotherapy delivered by disease-focused experts.
The Medical Oncology department provides comprehensive systemic cancer therapy, including cytotoxic chemotherapy, hormone therapy, small-molecule targeted agents, antibody-drug conjugates, bispecifics, checkpoint inhibitors, CAR-T referral coordination, and supportive care medications. Weekly multidisciplinary tumor boards ensure that each patient receives evidence-based, patient-centered treatment, integrating pathology, radiology, surgery, radiation oncology, genetics, and palliative care.
42
fellowship-trained medical oncologists across 6 disease-site teams25,000+
systemic therapy infusions and 4,200 oral targeted therapy starts in 202490%
molecular profiling rate for solid tumors at diagnosis250+
active clinical trial slots (Phase I–III) with 38% patient participationCommon Conditions & Subspecialty Clinics.
- Management of immune-related adverse events
- Pharmacogenomics-guided therapy
- Tumor-agnostic treatments (NTRK, MSI-H, TMB-high)
- Glioblastoma and low-grade gliomas
- Brain metastases management
- Temozolomide (TMZ), Tumor Treating Fields (TTFields)
- Vaccine and immunotherapy clinical trials
- Cutaneous and mucosal melanoma
- Merkel cell carcinoma
- PD-1 and LAG-3 checkpoint inhibitor combinations
- BRAF/MEK inhibitors, intralesional therapies
- Bone and soft-tissue sarcomas
- Gastrointestinal stromal tumors (GIST), desmoid tumors
- Tyrosine kinase inhibitors (TKIs)
- Integration with CyberKnife/SBRT for local control
- Prostate, bladder, kidney, and testicular cancers
- Androgen-receptor pathway inhibitors
- Immunotherapy and VEGF combination regimens
- Coordination for PSMA-targeted therapies
- Non-small cell lung cancer (NSCLC) — driver-positive & wild-type
- Small-cell lung cancer (SCLC) and mesothelioma
- Targeted therapy for EGFR, ALK, ROS1, MET mutations
- Immunotherapy and TKI resistance clinical trials
- HR-positive/HER2-negative breast cancer
- HER2-positive and triple-negative breast cancer
- Neoadjuvant chemotherapy and endocrine therapy
- Maintenance therapy with CDK4/6 and PARP inhibitors
Procedures & Treatments.
Early palliative-care co-management for symptom relief and QoL
Integration with cardio-oncology for LV function monitoring
Onco-fertility counseling and cryopreservation prior to gonadotoxic therapy
Anti-emetics per MASCC/ESMO guidelines, oral cryotherapy for mucositis
Growth-factor support (G-CSF), erythropoiesis-stimulating agents
Intrathecal Chemotherapy
For CNS prophylaxis/treatment in leukemia & lymphoma
Bisphosphonates & RANK-Ligand Inhibitors
Skeletal-related-event prevention
Hormone Therapy
SERMs, SERDs, aromatase inhibitors, androgen-receptor antagonists
Antibody-Drug Conjugates (ADC)
T-DM1, trastuzumab-deruxtecan, sacituzumab, enfortumab
Immunotherapy
PD-1/PD-L1, CTLA-4, LAG-3 inhibitors; bispecific T-cell engagers
Targeted Therapy
TKIs (EGFR, ALK, ROS1, RET, FGFR, BRAF, MEK), PARP inhibitors, CDK4/6 inhibitors, PI3K/mTOR inhibitors
Cytotoxic Chemotherapy
Dose-dense, metronomic, and hyperfractionated regimens
Liquid-biopsy MRD surveillance studies
Real-world evidence registry for TKI resistance and sequencing
First-in-human immunotherapy combinations (anti-TIM-3, TIGIT)
Phase I basket & umbrella trials targeting rare mutations
Care Pathway & Coordination.
Rapid Molecular Profiling
NGS and IHC results within 5–7 days of biopsy.
Tumor Board Consensus
Disease-site board formulates treatment algorithm and trial eligibility.
Treatment Education & Consent
Oncology nurse and pharmacist review regimen, side effects, and supportive medications.
Therapy Administration
Infusion in USP 800-compliant suite or oral targeted therapy with adherence app.
Monitoring & Response Assessment
Labs every cycle, imaging per RECIST 1.1, ctDNA tracking.
Survivorship / Next-Line Planning
Transition to survivorship clinic or next-line therapy; trial screening each line.
Technology & Facilities.
USP 800 Cleanroom Oncology Pharmacy
Robotic compounding and barcode verification
AI Symptom-Monitoring App
Patient-reported outcomes trigger nurse calls, reducing ED visits by 25%
Automated Infusion Pumps with Gravimetric Verification
On-Site NGS & ctDNA Lab
500-gene panel with 7-day TAT
Infusion Center
48 private bays with HEPA filtration, reclining chairs, and entertainment
Virtual Trial-Matching Platform
Real-time eligibility screening across global databases
